References

Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs

10.1093/rheumatology/keab609 · 2021 · External reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

10.1136/ard-2022-223356 · 2023 · External reference

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

10.1002/art.41752 · 2021 · External reference

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

10.3389/fphar.2021.680043 · 2021 · External reference

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.

10.3390/biom10071002 · 2020 · External reference

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.

10.1093/rheumatology/kes305 · 2013 · External reference

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

10.1053/j.gastro.2020.01.001 · 2020 · External reference

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.

10.1038/s41584-021-00726-8 · 2022 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

10.1002/art.1780310302 · 1988 · External reference

ACR/EULAR 2010 rheumatoid arthritis classification criteria.

2012 · External reference

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance

10.1136/annrheumdis-2015-207841 · 2015 · External reference

Unresolved reference

External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

Unresolved reference

External reference

Meta-analysis in clinical trials.

10.1016/0197-2456(86)90046-2 · 1986 · External reference

Metaprop: a Stata command to perform meta-analysis of binomial data.

10.1186/2049-3258-72-39 · 2014 · External reference

Quantifying heterogeneity in a meta-analysis.

10.1002/sim.1186 · 2002 · External reference

Comparison of two methods to detect publication bias in meta-analysis

10.1001/jama.295.6.676 · 2006 · External reference

Meta-Regression in Stata.

10.1177/1536867x0800800403 · 2008 · External reference

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.

10.1016/s2665-9913(22)00092-3 · 2022 · External reference

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

10.1016/s0140-6736(18)31115-2 · 2018 · External reference

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.

10.1093/rheumatology/keaa084 · 2020 · External reference

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.

10.1002/art.39801 · 2016 · External reference

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

10.1002/art.39808 · 2016 · External reference

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

10.1016/s0140-6736(18)31116-4 · 2018 · External reference

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.

10.1111/1756-185x.14235 · 2021 · External reference

SAT0257 A phase 2b/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic dmards

2018 · External reference

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

10.1136/annrheumdis-2016-210094 · 2017 · External reference

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

10.1002/art.39953 · 2017 · External reference

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

10.1136/annrheumdis-2014-206478 · 2015 · External reference

Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study

2020 · External reference

Baricitinib in Patients with Refractory Rheumatoid Arthritis

10.1056/nejmoa1507247 · 2016 · External reference

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

10.1056/nejmoa1608345 · 2017 · External reference

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind

2016 · External reference

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

10.1136/annrheumdis-2020-219214 · 2021 · External reference

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

10.1001/jama.2019.9055 · 2020 · External reference

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

10.1136/annrheumdis-2020-219213 · 2021 · External reference

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

10.1136/annrheumdis-2016-210104 · 2017 · External reference

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).

10.1136/annrheumdis-2016-210105 · 2017 · External reference

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

10.1136/annrheumdis-2014-206028 · 2015 · External reference

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

10.1016/s0140-6736(12)61424-x · 2013 · External reference

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

10.1002/art.37816 · 2013 · External reference

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.

10.1186/s13075-015-0612-7 · 2015 · External reference

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial

10.7326/0003-4819-159-4-201308200-00006 · 2013 · External reference

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

10.1002/art.24567 · 2009 · External reference

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.

10.1136/rmdopen-2019-001040 · 2019 · External reference

Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.

10.1002/acr.20494 · 2011 · External reference

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

10.3109/14397595.2014.995875 · 2015 · External reference

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

10.1056/nejmoa1112072 · 2012 · External reference

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.

10.1002/art.39955 · 2017 · External reference

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.

10.1136/annrheumdis-2015-208279 · 2016 · External reference

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.

10.1136/annrheumdis-2019-215164 · 2019 · External reference

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).

10.1136/annrheumdis-2019-215163 · 2019 · External reference

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.

10.1002/art.40054 · 2017 · External reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

10.1136/annrheumdis-2019-216655 · 2020 · External reference

The infection risks of JAK inhibition

10.1080/1744666x.2022.2014323 · 2022 · External reference

The emerging safety profile of JAK inhibitors in rheumatic disease.

10.1038/nrrheum.2017.23 · 2017 · External reference

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.

10.1093/rheumatology/kez087 · 2019 · External reference

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

10.1136/annrheumdis-2016-210457 · 2017 · External reference

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

10.1136/rmdopen-2020-001395 · 2020 · External reference

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies

10.3899/jrheum.130683 · 2014 · External reference

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

10.1136/annrheumdis-2021-221276 · 2022 · External reference

A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.

10.1038/s41598-017-07261-1 · 2017 · External reference

Simultaneous Assessment of mTORC1, JAK/STAT, and NLRP3 Inflammasome Activation Pathways in Patients with Sarcoidosis.

10.3390/ijms241612792 · 2023 · External reference

Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy

10.1186/s12964-023-01240-y · 2023 · External reference

Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review

10.1016/j.semarthrit.2022.152120 · 2023 · External reference

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

10.1136/annrheumdis-2015-207319 · 2016 · External reference

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

10.1136/annrheumdis-2019-216852 · 2020 · External reference

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.

10.3390/jcm11154459 · 2022 · External reference

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

10.1136/annrheumdis-2021-220822 · 2022 · External reference

JAK inhibitors and infections risk: focus on herpes zoster.

10.1177/1759720x20936059 · 2020 · External reference

Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis.

10.3389/fphar.2023.1241954 · 2023 · External reference

Development and Evaluation of a Fully Automated Molecular Assay Targeting the Mitochondrial Small Subunit rRNA Gene for the Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid Specimens

10.1016/j.jmoldx.2020.10.003 · 2020 · External reference

Cryptococcosis diagnosis and treatment: What do we know now

10.1016/j.fgb.2014.10.003 · 2015 · External reference

New developments in tuberculosis diagnosis and treatment

10.1183/20734735.0149-2021 · 2022 · External reference